Predictive Biomarkers and Targeted Therapies in the Skin

  • Aaron Phelan
  • Simon J. P. WarrenEmail author


A targeted therapy may be directed toward a specific cancer based on features of that cancer or a genomic subtype of that cancer based on the presence of druggable targets. A predictive biomarker is a biomarker that helps to predict how well a patient will respond to a particular treatment (in contrast, a prognostic biomarker helps to determine whether a cancer is likely to progress or is indolent in the absence of treatment). The last decade has seen significant progress in the use of targeted therapies in melanoma, basal cell carcinoma, and dermatofibrosarcoma protuberans and also the identification of relevant predictive biomarkers. Future promising directions include Merkel cell carcinoma. There is a need for those involved in the diagnosis and treatment of cutaneous cancers (including pathologists and dermatopathologists) to be aware of these exciting developments.


Melanoma Predictive biomarker Targeted therapy Merkel cell Basal cell Dermatofibrosarcoma 


  1. 1.
    Foth M, Wouters J, de Chaumont C, et al. Prognostic and predictive biomarkers in melanoma: an update. Expert Rev Mol Diagn. 2016;16:223–37.CrossRefPubMedGoogle Scholar
  2. 2.
    Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer. 2016;16:345–58.CrossRefPubMedGoogle Scholar
  3. 3.
    Rajkumar S, Watson IR. Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. Br J Cancer. 2016;115:145–55.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Fedorenko IV, Gibney GT, Sondak VK, et al. Beyond BRAF: where next for melanoma therapy? Br J Cancer. 2015;112:217–26.CrossRefPubMedGoogle Scholar
  5. 5.
    Hodi F, Corless C, Giobbie Hurder A, et al. Imatinib for melanomas harboring mutational activated or amplified Kit arising on mucosal, acral or chronically sun damaged skin. J Clin Oncol. 2013;31:3182–90.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Zhu Z, Liu W, Gotlieb V. The rapidly evolving therapies for advanced melanoma – towards immunotherapy, molecular targeted therapy, and beyond. Crit Rev Oncol Hematol. 2016;99:91–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA4 blockade in melanoma. New Eng J Med. 2014;371(23):2189–99.CrossRefPubMedGoogle Scholar
  8. 8.
    Allen V, Miao D, Schilling B, et al. Genomic correlates of response to CTLA4 blockade in metastatic melanoma. Science. 2015;350(6257):207–11.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7:95–106.CrossRefPubMedGoogle Scholar
  10. 10.
    Tumeh PC, Harview CL, Yearley JH, et al. PD1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ott PA, Hodi FS. Talimogene Laherparepvec for the treatment of advanced melanoma. Clin Cancer Res. 2016;22(13):3127–31.CrossRefPubMedGoogle Scholar
  12. 12.
    Athar M, et al. Sonic hedgehog signaling in Basal cell nevus syndrome. Cancer Res. 2014;74(18):4967–75.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib Mesylate in advanced dermatfibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010;28:1772–9.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 blockade with Pembrolizumab in advanced Merkel cell carcinoma. N Engl J Med. 2016;374:2542–52.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Paulson GP, et al. Transcriptome wide studies of Merkel cell carcinoma and validation of Intratumoral CD8+ lymphocyte invasion as independent risk factor of survival. J Clin Oncol. 2011;29:1539–46.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre single-group, open-label phase 2 trial. Lancet Oncol. 2016;17:1374–85.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Johnson DB, Puzanov I. Treatment of NRAS-mutant melanoma. Curr Treat Options in Oncol. 2015;16(15):1–12.Google Scholar
  18. 18.
    Greaves WO, Verma S, Patel KP, et al. Frequency and spectrum of BRAF mutations in a retrospective, single institution study of 1112 cases of melanoma. J Mol Diagn. 2013;15(2):220–6.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Pathology and Laboratory MedicineIndiana University School of MedicineIndianapolisUSA
  2. 2.Departments of Pathology and DermatologyIndiana UniversityIndianapolisUSA

Personalised recommendations